AtriCure, Inc. has seen continued momentum in Afib and related markets. The company sees solid revenue growth, which, amidst a retreat in the share price, has resulted in rapidly narrowing sales ...

New technology combines Pulsed Field Ablation (PFA) and Advanced Radiofrequency Ablation with AtriCure’s EnCompass ® clamp to reduce treatment time for surgical ablation patients MASON, Ohio, December ...

AtriCure's investors will have to wait a bit longer to find out if and when FDA will approve the company's Convergent hybrid ablation procedure for atrial fibrillation. There has been significant ...

Riverwater Partners, an investment management company, released its “Small Cap Strategy” Q2 2025 investor letter. A copy of the letter can be downloaded here. The Small Cap Core Strategy ...

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and ...

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and ...

AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left ...

UBS analyst Danielle Antalffy raised the firm’s price target on AtriCure (ATRC) to $40 from $35 and keeps a Buy rating on the shares. AtriCure posted an “exciting” quarter, even better than the ...

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, ...